PL1729773T3 - Monochlorowodorek 8-hydroksy-5-[(-hydroksy-2-[[(1R)-2-(4-metoksyfenylo) -1-metyloetylo]amino][etylo-2(1H)-chinolinonu w postaci krystalicznej oraz sposób jego wytwarzania - Google Patents

Monochlorowodorek 8-hydroksy-5-[(-hydroksy-2-[[(1R)-2-(4-metoksyfenylo) -1-metyloetylo]amino][etylo-2(1H)-chinolinonu w postaci krystalicznej oraz sposób jego wytwarzania

Info

Publication number
PL1729773T3
PL1729773T3 PL05730069T PL05730069T PL1729773T3 PL 1729773 T3 PL1729773 T3 PL 1729773T3 PL 05730069 T PL05730069 T PL 05730069T PL 05730069 T PL05730069 T PL 05730069T PL 1729773 T3 PL1729773 T3 PL 1729773T3
Authority
PL
Poland
Prior art keywords
hydroxy
methylethyl
methoxyphenyl
ethyl
amino
Prior art date
Application number
PL05730069T
Other languages
English (en)
Inventor
Fausto Pivetti
Roberto Pighi
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1729773(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of PL1729773T3 publication Critical patent/PL1729773T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL05730069T 2004-03-24 2005-03-24 Monochlorowodorek 8-hydroksy-5-[(-hydroksy-2-[[(1R)-2-(4-metoksyfenylo) -1-metyloetylo]amino][etylo-2(1H)-chinolinonu w postaci krystalicznej oraz sposób jego wytwarzania PL1729773T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04007045 2004-03-24
EP05730069A EP1729773B1 (en) 2004-03-24 2005-03-24 8-hydroxy-5- [(-hydroxy-2- [[ (1r)-2-(4-methoxyphenyl)-1-methylethyl] amino ][ethyl -2(1h)-quinolinone monohydrochloride in crystalline form and the process for its preparation
PCT/EP2005/003144 WO2005089760A1 (en) 2004-03-24 2005-03-24 8-hydroxy-5-[(-hydroxy-2-[[ (1r)-2-(4-methoxyphenyl)-1-methylethyl] amino ][ethyl] -2(1h)-quinolinone monohydrochloride in crystalline form and the process for its preparation

Publications (1)

Publication Number Publication Date
PL1729773T3 true PL1729773T3 (pl) 2008-12-31

Family

ID=34963779

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05730069T PL1729773T3 (pl) 2004-03-24 2005-03-24 Monochlorowodorek 8-hydroksy-5-[(-hydroksy-2-[[(1R)-2-(4-metoksyfenylo) -1-metyloetylo]amino][etylo-2(1H)-chinolinonu w postaci krystalicznej oraz sposób jego wytwarzania

Country Status (30)

Country Link
US (1) US20070197586A1 (pl)
EP (1) EP1729773B1 (pl)
JP (1) JP2007530489A (pl)
KR (1) KR20070001946A (pl)
CN (2) CN1929840B (pl)
AR (1) AR048339A1 (pl)
AT (1) ATE399552T1 (pl)
AU (1) AU2005224032A1 (pl)
BR (1) BRPI0508213A (pl)
CA (1) CA2560650A1 (pl)
CY (1) CY1108323T1 (pl)
DE (1) DE602005007871D1 (pl)
DK (1) DK1729773T3 (pl)
EA (1) EA010128B1 (pl)
ES (1) ES2309739T3 (pl)
HR (1) HRP20080495T3 (pl)
IL (1) IL178227A0 (pl)
MA (1) MA28549B1 (pl)
MX (1) MXPA06010515A (pl)
NO (1) NO20064274L (pl)
NZ (1) NZ550010A (pl)
PE (1) PE20060159A1 (pl)
PL (1) PL1729773T3 (pl)
PT (1) PT1729773E (pl)
RS (1) RS50602B (pl)
SI (1) SI1729773T1 (pl)
TN (1) TNSN06249A1 (pl)
UA (1) UA86221C2 (pl)
WO (1) WO2005089760A1 (pl)
ZA (1) ZA200607907B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1953143A1 (en) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116537A1 (en) 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116536A1 (en) 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride
WO2011015289A1 (en) 2009-08-04 2011-02-10 Chiesi Farmaceutici S.P.A. 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate
EP2360147A1 (en) 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GB9603237D0 (en) * 1996-02-16 1996-04-17 Sandoz Ltd Organic compounds
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
CA2534693A1 (en) * 2003-08-05 2005-02-17 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising steroids and a betamimetic
EP1953143A1 (en) * 2007-01-30 2008-08-06 CHIESI FARMACEUTICI S.p.A. Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116537A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
EP2116536A1 (en) * 2008-05-07 2009-11-11 CHIESI FARMACEUTICI S.p.A. Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride

Also Published As

Publication number Publication date
US20070197586A1 (en) 2007-08-23
WO2005089760A1 (en) 2005-09-29
EP1729773A1 (en) 2006-12-13
NZ550010A (en) 2010-08-27
CN1929840B (zh) 2010-12-08
ZA200607907B (en) 2008-04-30
EA200601531A1 (ru) 2007-04-27
BRPI0508213A (pt) 2007-07-17
HRP20080495T3 (en) 2008-11-30
AR048339A1 (es) 2006-04-19
MXPA06010515A (es) 2007-03-30
EA010128B1 (ru) 2008-06-30
CN101812017A (zh) 2010-08-25
NO20064274L (no) 2006-10-13
DK1729773T3 (da) 2008-10-20
KR20070001946A (ko) 2007-01-04
UA86221C2 (en) 2009-04-10
CA2560650A1 (en) 2005-09-29
PE20060159A1 (es) 2006-04-04
CY1108323T1 (el) 2014-02-12
TNSN06249A1 (en) 2007-12-03
MA28549B1 (fr) 2007-04-03
PT1729773E (pt) 2008-09-29
IL178227A0 (en) 2006-12-31
EP1729773B1 (en) 2008-07-02
SI1729773T1 (sl) 2008-10-31
CN1929840A (zh) 2007-03-14
DE602005007871D1 (de) 2008-08-14
ATE399552T1 (de) 2008-07-15
ES2309739T3 (es) 2008-12-16
AU2005224032A1 (en) 2005-09-29
RS50602B (sr) 2010-05-07
JP2007530489A (ja) 2007-11-01

Similar Documents

Publication Publication Date Title
IL162253A0 (en) Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
PL393289A1 (pl) Preparat pasożytniczy do stosowania miejscowego oraz sposób zapewniania aktywności przeciwpasożytniczej
IL178164A0 (en) Single crystals and methods for fabricating same
EP1968943A4 (en) IMPROVED METHOD FOR THE PRODUCTION OF MONTELUCASTAST AND THE PHARMACEUTICALLY SAFE SALTS
HK1082389A1 (en) Slide fastener stringer and method of manufacturing the same
PT1729773E (pt) Monocloridrato de 8-hidroxi-5-[(1r)-1-hidroxi-2-[[(1r)-2-(4- metoxifenil)-1-metiletil]amino]etil]-2(1h)-quinolinona na forma cristalina e o processo para a sua preparação
IL184297A (en) Indexable insert and method of manufacturing the same
IL181867A0 (en) Crystalline clopidogrel hydrobromide and processes for preparation thereof
IL173736A0 (en) Process for the preparation of renzapride and intermediates thereof
IL172802A0 (en) Aztreonam l-lysine and methods for the preparation thereof
WO2010060529A8 (en) Microparticles comprising a salt of 8-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)-quinolinone
IL181988A (en) N - (phenyl preserved in position 5 and converted in nitro in position 2) Reliable and methods for preparing h - benzimidazole in methyl in position 1 and also used in position 6
EP1883619A4 (en) PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRAFLUOROBENZYLANILINE COMPOUND AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
ZA200905291B (en) Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]-ethyl]-2(1H)-quinolinone monohydrochloride
SI1753720T1 (sl) Postopek za pripravo perindoprila in njegovih soli
HU3025U (en) Roller head for preparation of workpiece
PL1589014T3 (pl) Sposób syntezy pochodnych 1,3-dihydro-2H-3-benzazepin-2-onu i jego zastosowanie do wytwarzania iwabradyny i jej dopuszczalnych farmaceutycznie soli
IL183702A0 (en) Difluoronucleosides and process for preparation thereof
HK1113079A1 (en) Orally administrable antimalarial combined preparation and preparation process thereof
IL162255A0 (en) Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
IL173887A0 (en) A process for the preparation of cilostazol and of the intermediates thereof
ZA200405245B (en) Venlafaxine hydrochloride monohydrate and methods for the preparation thereof
IL190963A0 (en) Novel processes for the preparation of piperazinly and diazapanyl benzamide derivatives
IL182277A0 (en) Method and intermediates for the preparation of derivatives of n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulphonamide
SI1940790T1 (sl) Polimorfna oblika lerkanidipin hidroklorida in postopek za njegovo pripravo